According to the research report titled, “Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028”, available with MarketStudyReport, United States non-invasive prenatal testing market is expected to surpass USD 2.5 billion by the end of forecast period 2021-2028.
 

United States non-invasive prenatal testing (NIPT) market is anticipated to be driven by rising per capita income, development of advanced non-invasive testing products in this field, increased patient awareness, and heightened emphasis on medical reimbursement. Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4132710/ Furthermore, growing preference for non-invasive procedures over invasive technologies, as well as ACOG recommendations supporting NIPT for all pregnancies regardless of risk are projected to drive the market growth throughout the analysis period. For the uninitiated, non-invasive prenatal testing, also known as cell-free DNA testing, assists in finding genetic issues or abnormalities prior to birthing or throughout pregnancy term. Benefits such as 99% identification sensitivity and screening in less time than other prenatal screening forms will push non-invasive testing to become a common treatment in the future, replacing riskier screening approaches. Rising prevalence of genetic diseases such as Down syndrome, Edward syndrome, and Patau syndrome along with growing demand for prenatal genetic testing for identifying genetic abnormalities and determining fetal sex will continue to support the market development. Apart from the aforementioned, the research literature also touches on the restraints along with solutions for the same. The reimbursement environment of NIPT and regulatory framework in the U.S. also form a major part of the study. Elaborating on the competitive landscape, leading companies in United States non-invasive prenatal testing market are Integrated Genetics (LabCorp), Illumina, Inc., Natera Inc., Progenity Inc., Quest Diagnostics Inc., Myriad Genetics Inc., Centogene Inc., GenPath Inc., PerkinElmer Inc., Yourgene Health Inc., Invitae Corporation, Agilent Technologies Inc. and Ariosa Diagnostics Inc. (Roche) are the leading companies in United States non-invasive prenatal testing market. Industry players are focusing on undertaking licensing, distribution, and partnership deals, as well as R&D investments, to amplify their profit margins.